# Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct03015220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03015220](<https://clinicaltrials.gov/study/NCT03015220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03015220

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

## Technical summary

Registry record NCT03015220. Randomized; no masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2018-07-12 (actual). Results posted on 2019-12-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 458 participants (enrolled count; ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Started: 2017-01-10 (actual) (ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Primary completion: 2018-07-12 (actual) (ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Completion: 2018-07-12 (actual) (ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Results first posted: 2019-12-30 (ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03015220, source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03015220-2021-03-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
- Acronym: PIONEER 10
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Dulaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial (`cardio:pubmed-32333876`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9ff7898d5b1ab82c88314ad9b6afc19b749bf2237d5b9c8e415fdb23008e0882
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
